PALATINE, IL -- (Marketwired) -- 05/02/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three months ended March 31, 2013. The Company reported a net loss of $4.2 million for the first qua...

PALATINE, IL -- (Marketwired) -- 04/04/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the company has been issued U.S. Patent No. 8,409,616 by the United States Patent and Trademark Office. Claims in the patent cover, among other inventio...

PALATINE, IL -- (Marketwire) -- 03/05/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that its new next generation pseudoephedrine with abuse deterrent technology will now be stocked by chain drug store KERR DRUG. Nexafed® [pseudoephedrine hydrochloride (HCl)], is a 30 mg immediate-release pseudoephedrine product that comb...

PALATINE, IL -- (Marketwire) -- 02/22/13 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today that the Company will present at the Cowen and Company Health Care Conference at the Boston Marriott Copley Place on Tuesday, March 5, 201...

PALATINE, IL -- (Marketwire) -- 12/10/12 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced the launch of Nexafed® [pseudoephedrine hydrochloride (HCl)], a 30 mg immediate-release next generation pseudoephedrine product, combining effective nasal-congestion relief with a unique technology that disrupts the conversion of pseudoep...

PALATINE, IL -- (Marketwire) -- 11/06/12 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine months ended September 30, 2012. The Company reported a net loss of $2.2 million f...

PALATINE, IL--(Marketwire - Sep 26, 2012) - Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR ), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today a letter agreement with Pfizer Inc. providing for the termination of Pfizer's license to Acura's ...

PALATINE, IL--(Marketwire -08/22/12)- Acura Pharmaceuticals, Inc. (ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today that ...